Role of TGF-β1 and Its Receptors in Breast Carcinogenesis:Evaluation of Gene Expression Patterns and Clinical Implications

Wenjing Wang,Aesun Shin,Qiuyin Cai,Zefang Ren,Xiao-Ou Shu,Yutang Gao,Harold I. Moses,Wei Lu,Wei Zheng

DOI: https://doi.org/10.1007/s11805-007-0153-1

2007-01-01

Abstract:Transforming growth factor β1 (TGF-β1) is a multifunctional cytokine that may play an important role in tumor development and progression.

What problem does this paper attempt to address?

EXPRESSION OF TGF-β1AND TGF-β R II IN COLORECTAL ADENOMAS OF VARYING STAGES

Wang Da,He Chao,Ding Wei,Wang Hui-ping

DOI: https://doi.org/10.1007/bf02841187

2001-01-01

Journal of Zhejiang University SCIENCE A

Abstract:To study the function of transforming growth factor β1 (TGF-β1) and transforming growth factor-β type II receptor (TGF-βR II) in varying stages of colorectal adenoma during neoplastic transformation, fiftyfive cases of resected colorectal adenomas were examined immunohistochemically. Our results showed that the expression of TGF-β1 ranged from high to low, with the progression of low-grade to high-grade dysplasia of adenomas to carcinoma. And there was significantly different expression of TGF-β1 between moderate and high dysplasia adenomas (P<0.05), but no significantly different expression of TGF-β R II was found among varying stages of adenomas. Our results suggested that the quantities of TGF-β1 secreted by adenoma cells decrease dramatically in moderate to severe dysplasia colorectal adenomas. It is the decreased secretion of TGF-β1, rather than the mutated TGF-βR II that may play an important role in transforming colorectal adenomas to adenocarcinomas.
TGF-β-Regulated MicroRNAs and Their Function in Cancer Biology.

Pengyuan Yang,Yun Zhang,Geoffrey J Markowitz,Xing Guo,Xiao-Fan Wang

DOI: https://doi.org/10.1007/978-1-4939-2966-5_21

2016-01-01

Abstract:The transforming growth factor-β (TGF-β) is known to regulate a large number of biological processes and is involved in various aspects of tumor development. Recent studies have shown that the biogenesis of miRNAs can be regulated by TGF-β signaling directly via Smad-dependent mechanisms and/or other unknown mechanisms, which may induce autoregulatory feedback loops in response to the activation of TGF-β signaling, influencing the fate of tumor cells. In this chapter, we summarize the currently described mechanisms underlying TGF-β's regulation of miRNA biogenesis, and the functional role of TGF-β-regulated miRNAs in tumor initiation, epithelial-mesenchymal transition, and tumor microenvironment modulation. Finally, we introduce methods to study TGF-β-regulated miRNAs and their functions in tumor progression and metastasis using an example of publication from our lab demonstrating the presence of a TGF-β-miR-34a-CCL22 signaling axis, which serves as a potent etiological pathway for the development of hepatocellular carcinoma venous metastases.
The Role of TGF-β Signaling Pathways in Cancer and Its Potential as a Therapeutic Target

Yun Yang,Wen-Long Ye,Ruo-Nan Zhang,Xiao-Shun He,Jing-Ru Wang,Yu-Xuan Liu,Yi Wang,Xue-Mei Yang,Yu-Juan Zhang,Wen-Juan Gan

DOI: https://doi.org/10.1155/2021/6675208

2021-07-22

Abstract:The transforming growth factor-β (TGF-β) signaling pathway mediates various biological functions, and its dysregulation is closely related to the occurrence of malignant tumors. However, the role of TGF-β signaling in tumorigenesis and development is complex and contradictory. On the one hand, TGF-β signaling can exert antitumor effects by inhibiting proliferation or inducing apoptosis of cancer cells. On the other hand, TGF-β signaling may mediate oncogene effects by promoting metastasis, angiogenesis, and immune escape. This review summarizes the recent findings on molecular mechanisms of TGF-β signaling. Specifically, this review evaluates TGF-β′s therapeutic potential as a target by the following perspectives: ligands, receptors, and downstream signaling. We hope this review can trigger new ideas to improve the current clinical strategies to treat tumors related to the TGF-β signaling pathway.

integrative & complementary medicine
TGFBI Protein High Expression Predicts Poor Prognosis in Colorectal Cancer Patients.

Jing Zhu,Xijun Chen,Zhongcai Liao,Chao He,Xiaotong Hu

2015-01-01

Abstract:Transforming growth factor-beta-induced (TGFBI) serves as a linker protein and plays a role in the activa- tion of morphogenesis, cell proliferation, adhesion, migration, differentiation and inflammation. High expression levels of the human TGFBI gene are correlated with numerous human malignancies. In order to explore the roles of TGFBI in the tumor progression of colorectal cancer, colorectal cancer specimens from 115 patients with strict follow-up were selected for the analysis of TGFBI by immunohistochemistry. The correlations between TGFBI expres- sion and the clinicopathological features of colorectal cancers were evaluated. In the colorectal cancer tissues, TGFBI was mainly localized in the cytoplasm and stroma and scarcely in the nucleus. TGFBI expression in the cyto- plasm and stroma was not found to be associated with age, gender, tumor histopathological grading, PT category and tumor location (P > 0.05 for each). However, high TGFBI expression in the cytoplasm and stroma correlated with lymph node metastasis, distant metastasis and Dukes stage (P < 0.05 for each). The survival rate was significantly lower in patients with high TGFBI expression than in those with low TGFBI expression. Furthermore, we found that tumor node metastasis (TNM) staging (HR: 2.963; 95% CI: 1.573-1.664; P = 0.000), differentiation (HR: 1.574; 95% CI: 1.001-2.476; P = 0.049) and high TGFBI cytoplasmic expression (HR: 3.332; 95% CI: 1.410-7.873; P = 0.000) proved to be independent prognostic factors for survival in colorectal cancer. In conclusion, TGFBI plays an important role in the progression of colorectal cancers and it is an independent poor prognostic factor for colorectal cancer patients.
TGF-β Signaling Pathway1S Function in Tumor Initiation, Progression and Metastasis

WANG Tian-yu,FAN Yu,LI Dan,WANG Xi,WU Jing-yun,LUAN Li-ju,QIN Li-hua

DOI: https://doi.org/10.16695/j.cnki.1006-2947.2008.01.028

2008-01-01

Abstract:Transforming growth factors-β(TGF-β)are a class of cytokines with many kinds of biologic activity, which regulate cell proliferation,differentiation,development and apoptosis.According to the studies in recent years,TGF-βacts upon tumor through a broad and complex spectrum of interdependent interactions.In terms of sites,TGF-βsignaling pathways show a significant role in tumor suppression and tumor promotion by tumor-cell-autonomous effects,and also promote or suppress carcinoma progression and metastasis by affecting the tumor microenvironment,such as fibroblasts, immune cells and the extracellular matrix.In terms of stages,prior to initiation and early during progression TGF-βacts as a tumor suppressor restraining cell proliferation,initiating cell differentiation and inducing cell apoptosis,however at later stages in tumor progression it often acts in many ways to promote tumor migration and metastasis.The complex nature of TGF-βsignaling presents a unique challenge and an opportunity to discover the mechanism of tumor and to develop therapeutic intervention strategies for targeting cancer.
Expression of TGF-β1 and the mechanism of invasiveness and metastasis induced by TGF-β1 in breast cancer

Jian BAO,Zheng-sheng WU,Yue QI,Qiang WU,Feng YANG

DOI: https://doi.org/10.3760/cma.j.issn.0253-3766.2009.09.009

2009-01-01

Abstract:Objective To investigate the expression of MMP-2,TIMP-2,TGF-β1 and TGF-βRI and the relationship among them in breast cancer.Methods The protein expression of MMP-2,TIMP-2,TGF-β1 and TGF-β1R1 was detected on tissue chips by S-P immunohistochemical staining in 160 cases of breast carcinoma.Results The positive rates of TGF-β1,TGF-β1 mRNA,MMP-2,MMP-9,TIMP-1 and TIMP-2 expression were 73.7%,56.2%,96.9%,95.0%,87.5% and 89.4%,respectively.Axillary lymph node metastasis and TNM staging(P ＜0.01 and P ＜0.01,respectively)were positively correlated to the expression of TGF-β1.Relase-free survival of TGF-β1 positive group was lower than that of TGF-β1 negative group(P = 0.023).The expression of M MP-2 or M M P-9 was positively correlated to that of TGF-β1 (r=0.170,P＜0.05;r =0.221,P＜0.01)and was negatively correlated to that of TGF-β1 mRNA(r =-0.126,P ＞0.05;r = 0.019,P ＞ 0.05).Conclusion The expression of TGF-β1 may be closely correlated with the invasion and metastasis of breast cancer.TGF-β1-induced invasiveness and metastasis of breast cancer cells are mediated by MMP-2 and MMP-9.
TGF-β Ligands, TGF-β Receptors, and Lung Cancer

Guiying Y. Wang,Xiaochua H. Hu,Rongmei M. Zhang,Lindsey J. Leach,Zewei W. Luo

DOI: https://doi.org/10.1007/978-1-59745-293-9_6

2008-01-01

Abstract:Transforming growth factor-β (TGF-β) is a multifunctional cytokine involved in the regulation of proliferation, differentiation, migration, and apoptosis of many cells. In mammals, there are three TGF-β isoforms, encoded by different genes and showing partially overlapping as well as distinct functions. TGF-β is secreted as a precursor, requiring activation through a multistep process into the mature form. In most epithelial, endothelial, and hematopoietic cells, TGF-β is a potent inhibitor of cell proliferation. On the other hand, TGF-β induces extracellular matrix accumulation, angiogenesis, and immunosuppression, indicating that TGF-β facilitates progression of tumors under certain conditions. The TGF-β signaling pathway has been shown to include a tumor suppressor pathway in carcinogenesis, and many investigators now believe that development of resistance to TGF-β by tumor cells represents a key event in the progression of malignancy. In this chapter, we review the genetic mutations and epigenetic alterations of TGF-β ligands and receptors in human cancers, particularly lung cancer. It is also attempted to give an understanding of the TGF-β signaling pathway for the role of TGF-β signaling inhibitors as cancer therapeutics.
Expression of Transforming Growth Factor Β1 in Gastric Cancer and Its Clinical Value

卢震亚,黄怀德,厉有名,陈峰,蔡卫民

DOI: https://doi.org/10.3969/j.issn.1001-5930.2001.04.021

2001-01-01

Abstract:Objective To examine the expression of transforming Growth Factor β 1(TGF-β 1) in patients with gastric carcinoma and the clinical value.Methods Reverse transcription polymerase chain reaction add Dot blot analysis were used to examine TGF-β 1 mRNA levels in gastric cancer tissue,intenstinal metaplasia and normal stomach tissue.Results The gastric cancer had significantly higher TGF-β 1 mRNA levels(1.48±0.17) compared with normal tissues(0.88±0.08) paracancer tissue(0.92±0.11) and intenstinal metaplasia(1.00±0.14)(P0.01),while no significant difference was found between normal tissues and atrophic gastritis(P0.05).TGF-β 1 mRNA levels in early gastric cancer was significantly lower than those in progressive cancer(1.18±0.20 vs 1.54±0.20)(P 0.05),but higher than normal tissues.The TGF-β 1 mRNA level in group with metastatic lymph nodes was higher than those without metastatic lymph nodes(1.62±0.26 vs 1.25±0.19)(P0.05).Conclusion TGF-β 1 mRNA levels are associated with the gastric carcinogenesis,also associated with the node metastasis and invasion of gastric cancer.
TGF-beta Signaling in Cancer

Shuchen Gu,Xin-Hua Feng

DOI: https://doi.org/10.1093/abbs/gmy092

IF: 3.7

2018-01-01

Acta Biochimica et Biophysica Sinica

Abstract:Signals from the transforming growth factor-beta (TGF-beta) superfamily mediate a broad spectrum of cellular processes and are deregulated in many diseases, including cancer. TGF-beta signaling has dual roles in tumorigenesis. In the early phase of tumorigenesis, TGF-beta has tumor suppressive functions, primarily through cell cycle arrest and apoptosis. However, in the late stage of cancer, TGF-beta acts as a driver of tumor progression and metastasis by increasing tumor cell invasiveness and migration and promoting chemo-resistance. Here, we briefly review the mechanisms and functions of TGF-beta signaling during tumor progression and discuss the therapeutic potentials of targeting the TGF-beta pathway in cancer.
Biphasic Role of TGF-β in Cancer Progression: From Tumor Suppressor to Tumor Promotor

Chuannan Fan,Jing Zhang,Wan Hua,Peter ten Dijke

DOI: https://doi.org/10.1016/b978-0-12-801238-3.64983-8

2018-01-01

Abstract:Transforming growth factor-β (TGF-β) can elicit a biphasic effect on tumor progression by inhibiting cell proliferation and promoting apoptosis at early phases and promoting migration, epithelial to mesenchymal transition and invasion at late phases. Here, we review how TGF-β signaling pathways mediate potent cytostatic effects in normal and premalignant cells and how tumor cells become selectively resistant to these effects. In addition, we discuss how alterations in TGF-β signaling switch its behavior from tumor suppressor into tumor promoter. TGF-β not only acts directly on tumor cells but also facilitates a favorable microenvironment for rapid tumor growth and metastasis. Finally, we provide an overview of the opportunities and challenges for the therapeutic targeting of TGF-β-induced pro-oncogenic responses.
Transforming growth factor-induced gene TGFBI is correlated with the prognosis and immune infiltrations of breast cancer

Haiwei Wang,Xinrui Wang,Liangpu Xu

DOI: https://doi.org/10.1186/s12957-024-03301-z

2024-01-21

World Journal of Surgical Oncology

Abstract:Transforming growth factor β (TGFβ) is a critical regulator of lung metastasis of breast cancer and is correlated with the prognosis of breast cancer. However, not all TGFβ stimulated genes were functional and prognostic in breast cancer lung metastatic progress. In this study, we tried to determine the prognosis of TGFβ stimulated genes in breast cancer.

oncology,surgery
Pan-cancer analysis revealing the multidimensional expression and prognostic and immunologic roles of TGFB1 in cancer

Zhitao Chen,Chenchen Ding,Jun Chen,Shusen Zheng,Qiyong Li

DOI: https://doi.org/10.1177/03000605231221361

2024-01-25

Journal of International Medical Research

Abstract:Journal of International Medical Research, Volume 52, Issue 1, January 2024. ObjectiveThis study aimed to perform an integrated pan-cancer analysis to characterize the expression patterns, prognostic value, genetic alterations, and immunologic roles of transforming growth factor beta 1 (TGFB1) across diverse human cancer types.MethodsBioinformatics analyses were conducted using multiple public databases including The Cancer Genome Atlas, Genotype-Tissue Expression, Clinical Proteomic Tumor Analysis Consortium, TIMER2, GEPIA2, cBioPortal, StringDB, and others. Differential expression, survival, immune correlation, and protein interaction network analyses were performed.ResultsTGFB1 was overexpressed in several tumor types compared with that in normal tissues. High TGFB1 expression was associated with an advanced stage and poorer prognosis in certain cancers. TGFB1 mutations occurred in 1.3% of 10,967 cases surveyed. TGFB1 expression correlated with tumor-infiltrating immune cells and immunotherapy-related genes.ConclusionsThis comprehensive multi-omics analysis revealed the complex expression and prognostic landscape of TGFB1 across cancers. TGFB1 is emerging as a potential immunotherapeutic target in certain contexts. Further research should elucidate its multifaceted tumor-promoting and tumor-suppressive mechanisms. Our pan-cancer analysis provides new insights into TGFB1 as a prognostic biomarker and immunotherapeutic target in human cancers, and our findings may guide future preclinical and clinical investigations of TGFB1-directed therapies.

pharmacology & pharmacy,medicine, research & experimental
The role of TGFBI (βig-H3) in gastrointestinal tract tumorigenesis

Bing Han,Haolei Cai,Ying Chen,Bing Hu,Hongyu Luo,Yulian Wu,Jiangping Wu

DOI: https://doi.org/10.1186/s12943-015-0335-z

IF: 37.3

2015-01-01

Molecular Cancer

Abstract:Background TGFβ-induced (TGFBI/βig-H3) is a protein inducible by TGFβ1 and secreted by many types of cells. It binds to collagen, forms part of the extracellular matrix (ECM), and interacts with integrins on cell surfaces. In this study, we investigated the role of TGFBI in tumorigenesis and the underlying mechanisms. Methods Patient serum TGFBI levels were determined by ELISA. TGFBI transgenic and gene knockout mice and TGFBI-overexpressing liver cells were used for mechanistic studies. Results We demonstrated that patients with cholangiocarcinomas, hepatic carcinomas or gastric carcinomas presented significantly elevated serum TGFBI levels, and the excess TGFBI was derived from the tumor masses. TGFBI overexpression in mice resulted in increased incidence of spontaneous tumors and N,N-diethylnitrosamine (DEN)-induced liver tumor nodules, compared to that in wild type (WT) mice, while TGFBI knockout mice were comparable to WT controls in these 2 aspects. TGFBI promoted the survival of Aml-12 liver cells with DNA damage after irradiation, and augmented their post-irradiation proliferation. It activated the FAK/AKT/AKT1S1/PRS6/EIF4EBP pathway, which is known to modulate cell survival and proliferation. Conclusions Our data suggest that TGFBI functions as a promoter of certain gastrointestinal tract cancers. It provides a survival advantage to cells with DNA damage. Over a long time span, this advantage could translate into increased tumor risks.
TGFβ1: An Indicator for Tumor Immune Microenvironment of Colon Cancer From a Comprehensive Analysis of TCGA

Jinyan Wang,Jinqiu Wang,Quan Gu,Yan Yang,Yajun Ma,Quan’an Zhang

DOI: https://doi.org/10.3389/fgene.2021.612011

IF: 3.7

2021-04-28

Frontiers in Genetics

Abstract:Background Tumor microenvironment (TME) and tumor-infiltrating immune cells (TICs) greatly participate in the genesis and development of colon cancer (CC). However, there is little research exploring the dynamic modulation of TME. Methods We analyzed the proportion of immune/stromal component and TICs in the TME of 473 CC samples and 41 normal samples from The Cancer Genome Atlas (TCGA) database through ESTIMATE and CIBERSORT algorithms. Correlation analysis was conducted to evaluate the association between immune/stromal component in the TME and clinicopathological characteristics of CC patients. The difference analysis was performed to obtain the differentially expressed genes (DEGs). These DEGs were further analyzed by GO and KEGG enrichment analyses, PPI network, and COX regression analysis. Transforming growth factor β1 (TGFβ1) was finally overlapped from the above analysis. Paired analysis and GSEA were carried out to understand the role of TGFβ1 in colon cancer. The intersection between the difference analysis and correlation analysis was conducted to learn the association between TGFβ1 and TICs. Results Our results showed that the immune component in the TME was negatively related with the stages of CC. GO and KEGG enrichment analysis revealed that 1,110 DEGs obtained from the difference analysis were mainly enriched in immune-related activities. The intersection analysis between PPI network and COX regression analysis indicated that TGFβ1 was significantly associated with the communication of genes in the PPI network and the survival of CC patients. In addition, TGFβ1 was up-regulated in the tumor samples and significantly related with poor prognosis of CC patients. Further GSEA suggested that genes in the TGFβ1 up-regulated group were enriched in immune-related activities and the function of TGFβ1 might depend on the communications with TICs, including T cells CD4 naïve and T cells regulatory. Conclusion The expression of TGFβ1 might be an indicator for the tumor immune microenvironment of CC and serve as a prognostic factor. Drugs targeting TGFβ1 might be a potential immunotherapy for CC patients in the future.

genetics & heredity
Transforming growth factor-beta signaling and tumor angiogenesis.

Evangelia Pardali,Peter ten Dijke

DOI: https://doi.org/10.2741/3573

IF: 3.1

2009-01-01

Frontiers in Bioscience-Landmark

Abstract:Transforming growth factor-beta (TGF-beta) family members are secreted multifunctional cytokines that play pivotal roles in development and disease. The prototypic member of this family, TGF-beta, plays a dual role in carcinogenesis, acting as a tumor suppressor in early stages and as tumor promoter in late stages of tumor progression. Numerous studies support the notion that pathological angiogenesis is one of the hallmarks of cancer. Tumor angiogenesis is regulated by a network of growth factors, including members of the TGF-beta family. TGFbeta acts in a context-dependent manner and can either stimulate or inhibit tumor angiogenesis. In this review, we discuss our current understanding on how TGF-beta family members affect endothelial and smooth muscle cell function and how perturbed TGF-beta signaling may contribute to tumor angiogenesis and tumor progression.
Studying TGF-β Signaling and TGF-β-induced Epithelial-to-mesenchymal Transition in Breast Cancer and Normal Cells.

Jing Zhang,Midory Thorikay,Gerard van der Zon,Maarten van Dinther,Peter ten Dijke

DOI: https://doi.org/10.3791/61830

2020-01-01

Journal of Visualized Experiments

Abstract:Transforming growth factor-β (TGF-β) is a secreted multifunctional factor that plays a key role in intercellular communication. Perturbations of TGF-β signaling can lead to breast cancer. TGF-β elicits its effects on proliferation and differentiation via specific cell surface TGF-β type I and type II receptors (i.e., TβRI and TβRII) that contain an intrinsic serine/threonine kinase domain. Upon TGF-β-induced heteromeric complex formation, activated TβRI elicits intracellular signaling by phosphorylating SMAD2 and SMAD3. These activated SMADs form heteromeric complexes with SMAD4 to regulate specific target genes, including plasminogen activation inhibitor 1 (PAI-1, encoded by the SERPINE1 gene). The induction of epithelial-to-mesenchymal transition (EMT) allows epithelial cancer cells at the primary site or during colonization at distant sites to gain an invasive phenotype and drive tumor progression. TGF-β acts as a potent inducer of breast cancer invasion by driving EMT. Here, we describe systematic methods to investigate TGF-β signaling and EMT responses using premalignant human MCF10A-RAS (M2) cells and mouse NMuMG epithelial cells as examples. We describe methods to determine TGF-β-induced SMAD2 phosphorylation by Western blotting, SMAD3/SMAD4-dependent transcriptional activity using luciferase reporter activity and SERPINE1 target gene expression by quantitative real-time-polymerase chain reaction (qRT-PCR). In addition, methods are described to examine TGF-β-induced EMT by measuring changes in morphology, epithelial and mesenchymal marker expression, filamentous actin staining and immunofluorescence staining of E-cadherin. Two selective small molecule TGF-β receptor kinase inhibitors, GW788388 and SB431542, were used to block TGF-β-induced SMAD2 phosphorylation, target genes and changes in EMT marker expression. Moreover, we describe the transdifferentiation of mesenchymal breast Py2T murine epithelial tumor cells into adipocytes. Methods to examine TGF-β-induced signaling and EMT in breast cancer may contribute to new therapeutic approaches for breast cancer.
TGF-beta and Immune Cells: an Important Regulatory Axis in the Tumor Microenvironment and Progression.

Li Yang,Yanli Pang,Harold L Moses

DOI: https://doi.org/10.1016/j.it.2010.04.002

IF: 19.709

2010-01-01

Trends in Immunology

Abstract:Transforming growth factor beta (TGF-beta) plays an important role in tumor initiation and progression, functioning as both a suppressor and a promoter. The mechanisms underlying this dual role of TGF-beta remain unclear. TGF-beta exerts systemic immune suppression and inhibits host immunosurveillance. Neutralizing TGF-beta enhances CD8+ T-cell- and NK-cell-mediated anti-tumor immune responses. It also increases neutrophil-attracting chemokines resulting in recruitment and activation of neutrophils with an antitumor phenotype. In addition to its systemic effects, TGF-beta regulates infiltration of inflammatory/immune cells and cancer-associated fibroblasts in the tumor microenvironment causing direct changes in tumor cells. Understanding TGF-beta regulation at the interface of tumor and host immunity should provide insights into developing effective TGF-beta antagonists and biomarkers for patient selection and efficacy of TGF-beta antagonist treatment.
TGF-β-Mediated Epithelial-Mesenchymal Transition and Cancer Metastasis

Yang Hao,David Baker,Peter Ten Dijke,Peter ten Dijke

DOI: https://doi.org/10.3390/ijms20112767

IF: 5.6

2019-06-05

International Journal of Molecular Sciences

Abstract:Transforming growth factor β (TGF-β) is a secreted cytokine that regulates cell proliferation, migration, and the differentiation of a plethora of different cell types. Consistent with these findings, TGF-β plays a key role in controlling embryogenic development, inflammation, and tissue repair, as well as in maintaining adult tissue homeostasis. TGF-β elicits a broad range of context-dependent cellular responses, and consequently, alterations in TGF-β signaling have been implicated in many diseases, including cancer. During the early stages of tumorigenesis, TGF-β acts as a tumor suppressor by inducing cytostasis and the apoptosis of normal and premalignant cells. However, at later stages, when cancer cells have acquired oncogenic mutations and/or have lost tumor suppressor gene function, cells are resistant to TGF-β-induced growth arrest, and TGF-β functions as a tumor promotor by stimulating tumor cells to undergo the so-called epithelial-mesenchymal transition (EMT). The latter leads to metastasis and chemotherapy resistance. TGF-β further supports cancer growth and progression by activating tumor angiogenesis and cancer-associated fibroblasts and enabling the tumor to evade inhibitory immune responses. In this review, we will consider the role of TGF-β signaling in cell cycle arrest, apoptosis, EMT and cancer cell metastasis. In particular, we will highlight recent insights into the multistep and dynamically controlled process of TGF-β-induced EMT and the functions of miRNAs and long noncoding RNAs in this process. Finally, we will discuss how these new mechanistic insights might be exploited to develop novel therapeutic interventions.

biochemistry & molecular biology,chemistry, multidisciplinary
The Role of TGFBR3 in the Development of Lung Cancer

Xin Deng,Nuoya Ma,Junyu He,Fei Xu,Guoying Zou

DOI: https://doi.org/10.2174/0109298665315841240731060636

2024-08-27

Protein and Peptide Letters

Abstract:The Transforming Growth Factor-β (TGF-β) mediates embryonic development, maintains cellular homeostasis, regulates immune function, and is involved in a wide range of other biological processes. TGF-β superfamily signaling pathways play an important role in cancer development and can promote or inhibit tumorigenesis. Type III TGF-β receptor (TGFBR3) is a co-receptor in the TGF-β signaling pathway, which often occurs with reduced or complete loss of expression in many cancer patients and can act as a tumor suppressor gene. The reduction or deletion of TGFBR3 is more pronounced compared to other elements in the TGF-β signaling pathway. In recent years, lung cancer is one of the major malignant tumors that endanger human health, and its prognosis is poor. Recent studies have reported that TGFBR3 expression decreases to varying degrees in different types of lung cancer, both at the tissue level and at the cellular level. The invasion, metastasis, angiogenesis, and apoptosis of lung cancer cells are closely related to the expression of TGFBR3, which strengthens the inhibitory function of TGFBR3 in the evolution of lung cancer. This article reviews the mechanism of TGFBR3 in lung cancer and the influencing factors associated with TGFBR3. Clarifying the physiological function of TGFBR3 and its molecular mechanism in lung cancer is conducive to the diagnosis and treatment of lung cancer.

biochemistry & molecular biology
TGF-β1 Induces HMGA1 Expression in Human Breast Cancer Cells: Implications of the Involvement of HMGA1 in TGF-β Signaling

Xuyu Zu,Jing Zhong,Jingjing Tan,Li Tan,Dong Yang,Qinghai Zhang,Wenjun Ding,Wen Liu,Gebo Wen,Jianghua Liu,Renxian Cao,Yuyang Jiang

DOI: https://doi.org/10.3892/ijmm.2015.2062

IF: 5.314

2015-01-01

International Journal of Molecular Medicine

Abstract:Transforming growth factor-β1 (TGF-β1) signaling and high mobility group A (HMGA1) are known to play essential roles in the progression of breast cancer by inducing epithelial-mesenchymal transition. However, the correlation between TGF-β1 and HMGA1 in breast cancer cell is not yet well understood. In this study, we determined the effects of TGF-β1 on HMGA1 expression in breast cancer cells and examined the role of HMGA1 in breast cancer progression. Our results demonstrated that TGF-β1 induced the expression of HMGA1 in both MCF-7 and MDA-MB-231 breast cancer cells, as shown by RT-qPCR and immunofluorescence staining; however, the TGF-β1-induced expression of HMGA was blocked by treatment of the cells with phosphatidylinositol-3 kinase (PI3K) signaling inhibitors. Moreover, the HMGA1 promoter activity was found to be activated by TGF-β1 in the MCF-7 and MDA-MB-231 cells and we found that specificity protein 1 (Sp1) was involved in the TGF-β1-induced HMGA1 promoter activity, as shown by luciferase activity assay. Furthermore, the enforced expression of HMGA1 by transfection with a HMGA1 promoter enhanced cellular oncogenic properties, including proliferation, migration and invasion, and a tissue microarray revealed that breast tumors expressing human epidermal growth factor receptor 2 (HER2) showed higher expression levels of HMGA1 (P=0.007). In addition, higher HMGA1 expression levels were also observed in the ductal breast cancer cases compared with the lobular breast cancer cases (P=0.000). These findings establish the first link between HMGA1 and TGF-β1 in breast cancer, providing further evidence of the pivotal role of HMGA1 in breast cancer progression.

Role of TGF-β1 and Its Receptors in Breast Carcinogenesis:Evaluation of Gene Expression Patterns and Clinical Implications

EXPRESSION OF TGF-β1AND TGF-β R II IN COLORECTAL ADENOMAS OF VARYING STAGES

TGF-β-Regulated MicroRNAs and Their Function in Cancer Biology.

The Role of TGF-β Signaling Pathways in Cancer and Its Potential as a Therapeutic Target

TGFBI Protein High Expression Predicts Poor Prognosis in Colorectal Cancer Patients.

TGF-β Signaling Pathway1S Function in Tumor Initiation, Progression and Metastasis

Expression of TGF-β1 and the mechanism of invasiveness and metastasis induced by TGF-β1 in breast cancer

TGF-β Ligands, TGF-β Receptors, and Lung Cancer

Expression of Transforming Growth Factor Β1 in Gastric Cancer and Its Clinical Value

TGF-beta Signaling in Cancer

Biphasic Role of TGF-β in Cancer Progression: From Tumor Suppressor to Tumor Promotor

Transforming growth factor-induced gene TGFBI is correlated with the prognosis and immune infiltrations of breast cancer

Pan-cancer analysis revealing the multidimensional expression and prognostic and immunologic roles of TGFB1 in cancer

The role of TGFBI (βig-H3) in gastrointestinal tract tumorigenesis

TGFβ1: An Indicator for Tumor Immune Microenvironment of Colon Cancer From a Comprehensive Analysis of TCGA

Transforming growth factor-beta signaling and tumor angiogenesis.

Studying TGF-β Signaling and TGF-β-induced Epithelial-to-mesenchymal Transition in Breast Cancer and Normal Cells.

TGF-beta and Immune Cells: an Important Regulatory Axis in the Tumor Microenvironment and Progression.

TGF-β-Mediated Epithelial-Mesenchymal Transition and Cancer Metastasis

The Role of TGFBR3 in the Development of Lung Cancer

TGF-β1 Induces HMGA1 Expression in Human Breast Cancer Cells: Implications of the Involvement of HMGA1 in TGF-β Signaling